Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Note
  • Published:

Antisense DNA cocktail therapy using short ß-1,3-glucan/oligonucleotide complexes

Polymer Journal volume 55, pages 283–288 (2023)Cite this article

Subjects

Abstract

Developing an appropriate delivery vehicle for antisense oligonucleotides (AS-ODNs) to improve efficiency has been a central issue for translating antisense therapy into practice. We have proposed a macromolecular complex made from AS-ODNs and β-glucan, schizophyllan (SPG) as such a tool. We recently discovered a low molecular weight complex in which only one ODNs can be complexed and denoted it as a “quantized complex”.  This quantized complex can transfer AS-ODNs into cytosol more efficiently than the conventional large molecular weight complexes. Building on this previous work, this paper presents a new idea of delivering two different AS-ODNs (K-ras and YB-1) simultaneously to the same target cell to synergistically suppress the growth of cancer cells.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on SpringerLink
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Fig. 1
Fig. 2
Fig. 3
Fig. 4

References

  1. Hagedorn PH, Hansen BR, Koch T, Lindow M. Managing the sequence-specificity of antisense oligonucleotides in drug discovery. Nucleic Acids Res. 2017;45:2262–82.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  2. Khar R, Warsi M, Akhter S, Ahmad F, Jain G, Mallick N, et al. Nano-vectors for the ocular delivery of nucleic acid-based therapeutics. Indian J Pharm Sci. 2010;72:675.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  3. Zamecnik PC, Stephenson ML. Inhibition of Rous sarcoma virus replication and cell transformation by a specific oligodeoxynucleotide. Proc Natl Acad Sci USA. 1978;75:280–4.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  4. Zhu L, Mahato RI. Lipid and polymeric carrier-mediated nucleic acid delivery. Expert Opin Drug Deliv. 2010;7:1209–26.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  5. Xu L, Huang CC, Huang W, Tang WH, Rait A, Yin YZ, et al. Systemic tumor-targeted gene delivery by anti-transferrin receptor scFv-immunoliposomes. Mol Cancer Ther. 2002;1:337–46.

    CAS  PubMed  Google Scholar 

  6. Kim YT, Kim EH, Cheong C, Williams DL, Kim CW, Lim ST. Structural characterization of beta-D-(1 -> 3, 1 -> 6)-linked glucans using NMR spectroscopy. Carbohydr Res. 2000;328:331–41.

    Article  CAS  PubMed  Google Scholar 

  7. Adachi Y, Ishii T, Ikeda Y, Hoshino A, Tamura H, Aketagawa J, et al. Characterization of β-Glucan recognition site on C-Type Lectin, Dectin 1. Infect Immun. 2004;72:4159–71.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  8. McIntire TM, Brant DA. Observations of the (1→3)-β-d-Glucan linear triple helix to macrocycle interconversion using noncontact atomic force microscopy. J Am Chem Soc. 1998;120:6909–19.

    Article  CAS  Google Scholar 

  9. Sakurai K, Shinkai S. Molecular recognition of adenine, cytosine, and uracil in a single-stranded RNA by a natural polysaccharide: Schizophyllan. J Am Chem Soc. 2000;122:4520–1.

    Article  CAS  Google Scholar 

  10. Mochizuki S, Sakaurai K. β-1,3-Glucan/antisense oligonucleotide complex stabilized with phosphorothioation and its gene suppression. Bioorg Chem. 2010;38:260–4.

    Article  CAS  PubMed  Google Scholar 

  11. Sumiya K, Matsunaga T, Tanaka M, Mochizuki S, Sakurai K. Oligo-DNA Stoichiometrically binds β-1,3-Glucan with the best fit length. Biomacromolecules. 2020;21:4823–34.

    Article  CAS  PubMed  Google Scholar 

  12. Sumiya K, Izumi H, Matsunaga T, Tanaka M, Sakurai K. Delivery of therapeutic oligonucleotides targeting Dectin-1 using quantized complexes. Polym J. 2022;54:591–601.

    Article  CAS  Google Scholar 

  13. Izumi H, Nagao S, Mochizuki S, Fujiwara N, Sakurai K, Morimoto Y. Optimal sequence of antisense DNA to silence YB-1 in lung cancer by use of a novel polysaccharide drug delivery system. Int J Oncol. 2016;48:2472–8.

    Article  CAS  PubMed  Google Scholar 

  14. Fujiwara N, Izumi H, Morimoto Y, Sakurai K, Mochizuki S. Complex consisting of antisense DNA and β-glucan promotes internalization into cell through Dectin-1 and hybridizes with target mRNA in cytosol. Cancer Gene Ther. 2019;26:32–40.

    Article  CAS  PubMed  Google Scholar 

  15. Sasaki S, Izumi H, Morimoto Y, Sakurai K, Mochizuki S. Induction of potent cell growth inhibition by schizophyllan/K-ras antisense complex in combination with gemcitabine. Bioorg Med Chem. 2020;28:115668.

    Article  CAS  PubMed  Google Scholar 

  16. Yin Q, Zheng M, Luo Q, Jiang D, Zhang H, Chen C. YB-1 as an Oncoprotein: Functions, regulation, post-translational modifications, and targeted therapy. Cells. 2022;11:1217.

    Article  PubMed  PubMed Central  Google Scholar 

Download references

Acknowledgements

We gratefully would like to thank Takuya Matsunaga and Motoko Tanaka for technical help. This work was financially supported by JSPS KAKENHI and by JST: Grant-in-Aid for Scientific Research A (20H00668), Grant-in-Aid for Challenging Exploratory Research (20K20449), and Kitakyushu Innovative Human Resource and Regional Development Program (JPMJSP2149).

Author information

Authors and Affiliations

  1. Department of Chemistry and Biochemistry, University of Kitakyushu, 1-1 Hibikino, Kitakyushu, Fukuoka, 808-0135, Japan

    Yuki Hata, Kazuki Sumiya & Kazuo Sakurai

  2. Department of Occupational Pneumology, Institute of Industrial Ecological Sciences, University of Occupational and Environmental Health, 1-1 Isegaoka, Yahatanishi-ku, Kitakyushu, Fukuoka, 807-8555, Japan

    Hiroto Izumi

Authors
  1. Yuki Hata
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Kazuki Sumiya
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Hiroto Izumi
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Kazuo Sakurai
    View author publications

    You can also search for this author in PubMed Google Scholar

Contributions

YH and KS contributed equally to this work. This manuscript was written through contributions of all authors. All authors have given approval to the last version of the manuscript.

Corresponding authors

Correspondence to Hiroto Izumi or Kazuo Sakurai.

Ethics declarations

Conflict of interest

The authors declare no competing interests.

Additional information

Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Supplementary information

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Hata, Y., Sumiya, K., Izumi, H. et al. Antisense DNA cocktail therapy using short ß-1,3-glucan/oligonucleotide complexes. Polym J 55, 283–288 (2023). https://doi.org/10.1038/s41428-022-00720-1

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/s41428-022-00720-1

Search

Advanced search

Quick links